M
Martin Merschhemke
Researcher at Novartis
Publications - 21
Citations - 1318
Martin Merschhemke is an academic researcher from Novartis. The author has contributed to research in topics: Fingolimod & Multiple sclerosis. The author has an hindex of 11, co-authored 21 publications receiving 826 citations. Previous affiliations of Martin Merschhemke include University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred D. Lublin,David Miller,Mark S. Freedman,Bruce A.C. Cree,Jerry S. Wolinsky,Howard L. Weiner,Catherine Lubetzki,Hans-Peter Hartung,Xavier Montalban,Bernard M. J. Uitdehaag,Martin Merschhemke,Bingbing Li,Norman Putzki,Fonda Liu,Dieter A. Häring,Ludwig Kappos +15 more
TL;DR: A novel primary composite endpoint was used based on change from baseline in Expanded Disability Status Scale (EDSS), 25' Timed-Walk Test, or Nine-Hole Peg Test to assess time to 3-month confirmed disability progression in study participants treated for at least 3 years.
Journal ArticleDOI
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Stephen L. Hauser,Amit Bar-Or,Jeffrey A. Cohen,Giancarlo Comi,Jorge Correale,Patricia K. Coyle,Anne H. Cross,Jérôme De Seze,David Leppert,Xavier Montalban,Krzysztof Selmaj,Heinz Wiendl,Cecile Kerloeguen,Roman Willi,Bingbing Li,Algirdas Kakarieka,Davorka Tomic,Alexandra Goodyear,Ratnakar Pingili,Dieter A. Häring,Krishnan Ramanathan,Martin Merschhemke,Ludwig Kappos,Ludwig Kappos +23 more
TL;DR: Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide, and this data indicates that this drug should be considered as a second-line treatment for relapsing multiple sclerosis.
Journal ArticleDOI
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
Tanuja Chitnis,Douglas L. Arnold,Brenda Banwell,Wolfgang Brück,Angelo Ghezzi,Gavin Giovannoni,Benjamin Greenberg,Lauren B. Krupp,Kevin Rostasy,Marc Tardieu,Emmanuelle Waubant,Jerry S. Wolinsky,Amit Bar-Or,Tracy Stites,Yu Chen,Norman Putzki,Martin Merschhemke,Jutta Gärtner +17 more
TL;DR: Among pediatric patients with relapsing multiple sclerosis, fingolimod was associated with a lower rate of relapse and less accumulation of lesions on MRI over a 2‐year period than interferon beta‐1a but was associatedWith a higher rate of serious adverse events.
Journal ArticleDOI
AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study
Fabrizio Stocchi,Olivier Rascol,Alain Destée,Nobutaka Hattori,Robert A. Hauser,Anthony E. Lang,Werner Poewe,Mark Stacy,Eduardo Tolosa,Haitao Gao,Jennifer Nagel,Martin Merschhemke,Ana Graf,Christopher Kenney,Claudia Trenkwalder +14 more
TL;DR: AFQ056 demonstrated anti‐dyskinetic efficacy in this population without worsening underlying motor symptoms and will guide dose selection for future clinical trials.
Journal ArticleDOI
Progressive multifocal leukoencephalopathy after fingolimod treatment.
Joseph R. Berger,Bruce A.C. Cree,Benjamin Greenberg,Bernhard Hemmer,Brian J. Ward,Victor M. Dong,Martin Merschhemke +6 more
TL;DR: The characteristics of the 15 patients with fingolimod-associated progressive multifocal leukoencephalopathy identified from the Novartis data safety base and risk estimates for the disorder are described and the risk and incidence are estimated.